Castle Biosciences, Inc. (USD) Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.

Castle Biosciences, Inc. (USD) Active

505 South Friendswood Drive, Friendswood, TX, US, 77546

Stock Price USD

Price Change

Last Dividend USD

C+

Latest Rating

CSTL's stock peer is AMN (AMN Healthcare Services, Inc.)

CSTL's stock peer is DRIO (DarioHealth Corp.)

CSTL's stock peer is EMBC (Embecta Corp.)

CSTL's stock peer is EVH (Evolent Health, Inc.)

CSTL's stock peer is FLGT (Fulgent Genetics, Inc.)

CSTL's stock peer is GERN (Geron Corporation)

CSTL's stock peer is MYGN (Myriad Genetics, Inc.)

CSTL's stock peer is PSNL (Personalis, Inc.)

CSTL's stock peer is VIR (Vir Biotechnology, Inc.)

Healthcare Medical - Diagnostics & Research

Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.

80%

Dcf Rating

20%

Return On Equity

20%

Return On Assets

60%

Debt To Equity

20%

Price To Earnings

60%

Price To Book

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
Dividend Data Not Exist

Recent News

DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy

Newly published prospective study shows DecisionDx-Melanoma's i31-SLNB test result more accurately identifies patients at low and high risk of sentinel lymph node (SLN) positivity than the Melanoma Institute Australia (MIA) nomogram Patients classified as low risk by the i31-SLNB result had a 2.6% observed SLN positivity rate, falling well below the National Comprehensive Cancer Network (NCCN) 5% threshold used to consider avoiding sentinel lymph node biopsy (SLNB), compared with a 5.8% observed positivity rate for the MIA nomogram FRIENDSWOOD, Texas, June 25, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a prospective, multicenter study in Dermatology and Therapy demonstrating that DecisionDx-Melanoma's integrated sentinel lymph node biopsy test result (i31-SLNB) outperforms the MIA nomogram in identifying patients at low and high risk of SLN positivity, supporting more informed SLNB decision-making for patients with cutaneous melanoma (CM).1 This is the second multicenter study showing that the i31-SLNB result outperforms the MIA nomogram in assessing SLN positivity risk.2 "Many clinicians are familiar with nomograms that estimate risk of sentinel lymph node positivity using clinicopathologic features alone, yet current guidelines acknowledge limitations in their performance at lower risk thresholds," said Rohit Sharma, M.D., FACS, lead author of the study and surgical oncologist at Marshfield Clinic Health System in Marshfield, Wisconsin.

2026-06-25 16:30:00

Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal

Stokes was one of 22 financial leaders recognized in the Greater Houston area FRIENDSWOOD, Texas, June 23, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Frank Stokes, its chief financial officer, has been named a 2026 CFO Awards honoree by the Houston Business Journal. Stokes is among 22 chief financial officers from across the Greater Houston area recognized for their financial leadership and contributions to their organizations' success.

2026-06-23 07:00:00

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FRIENDSWOOD, Texas, June 19, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on June 15, 2026, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 172 employees covering an aggregate of 204,925 shares of common stock as an inducement material to their entering into employment with Castle Biosciences. The RSUs were granted pursuant to the Company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

2026-06-19 07:00:00

First Patient Enrolled in New Study Assessing early prediction of flares in Atopic Dermatitis by Castle Biosciences in Collaboration with SciBase

STOCKHOLM, June 10, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-powered skin health solutions, today announced that the first patient has been enrolled in a new study to assess flare prediction in Atopic Dermatitis. The primary objective of the multicenter prospective clinical study is to assess the prediction of flares in atopic dermatitis (AD).

2026-06-10 03:05:00

Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference

FRIENDSWOOD, Texas, May 13, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 1:20 p.m. Eastern time.

2026-05-13 07:00:00

Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation

This marks the fifth MedTech Breakthrough Award that Castle has earned for its innovative testing solutions FRIENDSWOOD, Texas, May 12, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its AdvanceAD-Tx test has been selected as the winner of the "Genomics Innovation Award" in the 10th annual MedTech Breakthrough Awards program, which recognizes companies driving meaningful progress and improving patient care across the global health and medical technology industry. AdvanceAD-Tx is Castle's clinically validated gene expression profile (GEP) test designed to guide systemic treatment decision making in patients 12 and older with moderate-to-severe atopic dermatitis (AD).

2026-05-12 07:00:00

Castle Biosciences Reports First Quarter 2026 Results

Delivered Q1 2026 revenue of $83.7 million Q1 2026 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 36% over Q1 2025 Raising full-year 2026 revenue guidance to $345-355 million from $340-350 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, May 6, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2026.

2026-05-06 16:05:00

Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month

Longstanding collaborations with AIM at Melanoma, the Melanoma Research Foundation, The Skin Cancer Foundation, IMPACT Melanoma and The Sun Bus continue to advance awareness and education throughout May FRIENDSWOOD, Texas, May 5, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its participation in a series of initiatives throughout May to celebrate Skin Cancer Awareness Month, including advocacy walks, community skin cancer screenings and patient education programs nationwide. These efforts are part of the Company's longstanding collaborations with multiple patient-focused organizations and ongoing commitment to advancing early detection, patient education and advocacy.

2026-05-05 07:00:00

New Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett's Esophagus

Clinical studies from Mayo Clinic researchers demonstrate the TissueCypher test provides improved risk stratification and influences risk-aligned surveillance decisions in clinical practice, with one study showing changes in surveillance intervals in more than half of patients compared with recommendations guided by traditional histopathology, supporting more personalized, risk-aligned patient management. FRIENDSWOOD, Texas, May 4, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data generated by researchers at Mayo Clinic will be presented at Digestive Disease Week® (DDW 2026), taking place May 2–5 in Chicago.

2026-05-04 07:00:00

Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS

Multi-center clinical and population-based data show that DecisionDx-Melanoma identifies biologically high-risk patients—including those with thin and early-stage disease—and provides recurrence risk insights to guide more precise, risk-aligned clinical management FRIENDSWOOD, Texas, April 21, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it will present new data on its DecisionDx-Melanoma test addressing a critical clinical challenge in melanoma care: identifying which patients with early-stage disease are at risk for poor outcomes and may benefit from intensified management. The data will be presented at the 22nd European Congress of Dermato-Oncology (EADO) Congress and the American College of Mohs Surgery (ACMS) 58th Annual Meeting.

2026-04-21 07:00:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions